$OMER
OMEROS CORP

2020 Q4 Form 10-Q Financial Statement

#000155837020013359 Filed on November 09, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q4
Revenue $10.63M $26.11M $33.42M
YoY Change -68.18% -12.53% 51.78%
Cost Of Revenue $90.00K $401.0K $400.0K
YoY Change -77.5% 44.24% 150.0%
Gross Profit $10.55M $25.71M $33.02M
YoY Change -68.05% -13.07% 51.05%
Gross Profit Margin 99.23% 98.46% 98.81%
Selling, General & Admin $17.90M $19.83M $16.13M
YoY Change 10.97% 17.13% 8.33%
% of Gross Profit 169.67% 77.12% 48.85%
Research & Development $26.46M $31.32M $40.59M
YoY Change -34.81% 31.88% 59.49%
% of Gross Profit 250.81% 121.79% 122.93%
Depreciation & Amortization $400.0K $410.0K $530.0K
YoY Change -24.53% -4.65% 70.97%
% of Gross Profit 3.79% 1.59% 1.61%
Operating Expenses $44.36M $31.32M $56.72M
YoY Change -21.79% 31.88% 40.08%
Operating Profit -$33.82M -$25.43M -$23.70M
YoY Change 42.66% 129.06% 28.31%
Interest Expense -$7.990M $6.882M -$5.810M
YoY Change 37.52% 20.42% 12.82%
% of Operating Profit
Other Income/Expense, Net $370.0K -$633.0K $290.0K
YoY Change 27.59% -279.32% 93.33%
Pretax Income -$41.43M -$46.32M -$29.23M
YoY Change 41.74% 181.34% -19.83%
Income Tax -$4.160M -$7.854M
% Of Pretax Income
Net Earnings -$37.27M -$38.46M -$29.23M
YoY Change 27.54% 133.63% 24.18%
Net Earnings / Revenue -350.57% -147.29% -87.46%
Basic Earnings Per Share -$0.66
Diluted Earnings Per Share -$604.4K -$0.66 -$577.4K
COMMON SHARES
Basic Shares Outstanding 61.65M 58.23M 49.75M
Diluted Shares Outstanding 58.23M

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $135.0M $153.5M $60.80M
YoY Change 122.04% 462.27% 0.5%
Cash & Equivalents $10.50M $21.10M $3.100M
Short-Term Investments $124.5M $132.4M $57.70M
Other Short-Term Assets $11.10M $3.500M $6.600M
YoY Change 68.18% -35.19% 1.54%
Inventory $1.355M $1.542M $1.147M
Prepaid Expenses
Receivables $3.800M $37.20M $35.10M
Other Receivables $70.00K $161.0K $111.0K
Total Short-Term Assets $151.3M $196.0M $103.7M
YoY Change 45.82% 207.19% 15.44%
LONG-TERM ASSETS
Property, Plant & Equipment $28.10M $2.950M $3.829M
YoY Change 633.87% -22.1% -0.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.700M $2.000M $2.300M
YoY Change -26.09% -16.67% 4.55%
Total Long-Term Assets $29.76M $31.09M $33.22M
YoY Change -10.44% 13.2% 447.44%
TOTAL ASSETS
Total Short-Term Assets $151.3M $196.0M $103.7M
Total Long-Term Assets $29.76M $31.09M $33.22M
Total Assets $181.0M $227.1M $137.0M
YoY Change 32.18% 148.81% 42.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.199M $7.017M $5.328M
YoY Change -21.19% -27.67% -15.17%
Accrued Expenses $28.76M $36.95M $46.63M
YoY Change -38.33% 8.68% 54.47%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.000M $1.100M $1.200M
YoY Change -16.67% 0.0% 34.98%
Total Short-Term Liabilities $36.74M $47.72M $55.46M
YoY Change -33.76% 2.07% 48.46%
LONG-TERM LIABILITIES
Long-Term Debt $237.0M $233.8M $159.8M
YoY Change 48.31% 48.73% 6.11%
Other Long-Term Liabilities $28.00M $28.80M $30.80M
YoY Change -9.09% 5.88% 275.61%
Total Long-Term Liabilities $265.0M $262.6M $190.6M
YoY Change 39.03% 42.41% 20.03%
TOTAL LIABILITIES
Total Short-Term Liabilities $36.74M $47.72M $55.46M
Total Long-Term Liabilities $265.0M $262.6M $190.6M
Total Liabilities $301.8M $314.4M $246.0M
YoY Change 22.68% 35.99% 25.45%
SHAREHOLDERS EQUITY
Retained Earnings -$872.7M -$835.4M -$734.6M
YoY Change 18.79% 18.43% 13.0%
Common Stock $751.9M $748.1M $625.6M
YoY Change 20.19% 32.29% 13.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$120.8M -$87.33M -$109.0M
YoY Change
Total Liabilities & Shareholders Equity $181.0M $227.1M $137.0M
YoY Change 32.18% 148.81% 42.77%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q4
OPERATING ACTIVITIES
Net Income -$37.27M -$38.46M -$29.23M
YoY Change 27.54% 133.63% 24.18%
Depreciation, Depletion And Amortization $400.0K $410.0K $530.0K
YoY Change -24.53% -4.65% 70.97%
Cash From Operating Activities -$18.41M -$34.94M -$23.01M
YoY Change -19.99% 364.63% -6.69%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$70.00K -$10.00K
YoY Change -100.0% 75.0% -90.0%
Acquisitions
YoY Change
Other Investing Activities $7.990M -$118.3M -$39.23M
YoY Change -120.37% -1361.41% 1628.19%
Cash From Investing Activities $8.000M -$118.4M -$39.24M
YoY Change -120.39% -1367.67% 1562.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $93.70M $54.20M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -170.0K 172.5M 56.48M
YoY Change -100.3% 5535.62% 87.7%
NET CHANGE
Cash From Operating Activities -18.41M -34.94M -23.01M
Cash From Investing Activities 8.000M -118.4M -39.24M
Cash From Financing Activities -170.0K 172.5M 56.48M
Net Change In Cash -10.58M 19.11M -5.770M
YoY Change 83.36% 291.6% -287.95%
FREE CASH FLOW
Cash From Operating Activities -$18.41M -$34.94M -$23.01M
Capital Expenditures $0.00 -$70.00K -$10.00K
Free Cash Flow -$18.41M -$34.87M -$23.00M
YoY Change -19.96% 366.18% -6.35%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001285819
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
CY2019Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
CY2020Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2019Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2020Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54200810
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61651152
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34475
dei Entity Registrant Name
EntityRegistrantName
OMEROS CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1663741
dei Entity Address Address Line1
EntityAddressAddressLine1
201 Elliott Avenue West
dei Entity Address City Or Town
EntityAddressCityOrTown
Seattle
dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98119
dei City Area Code
CityAreaCode
206
dei Local Phone Number
LocalPhoneNumber
676-5000
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
OMER
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
61652326
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21075000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3084000
CY2020Q3 us-gaap Short Term Investments
ShortTermInvestments
132448000
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
57704000
CY2020Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
37379000
CY2019Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
35185000
CY2020Q3 us-gaap Inventory Net
InventoryNet
1542000
CY2019Q4 us-gaap Inventory Net
InventoryNet
1147000
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3541000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6625000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
195985000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
103745000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2950000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3829000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26116000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
27082000
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1154000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1154000
CY2020Q3 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
870000
CY2019Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
1159000
CY2020Q3 us-gaap Assets
Assets
227075000
CY2019Q4 us-gaap Assets
Assets
136969000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
7017000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5328000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
36948000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
46627000
CY2020Q3 omer Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
3754000
CY2019Q4 omer Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
3504000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
47719000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
55459000
CY2020Q3 omer Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
29717000
CY2019Q4 omer Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
32318000
CY2020Q3 us-gaap Senior Long Term Notes
SeniorLongTermNotes
232808000
CY2019Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
158213000
CY2020Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
4157000
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61651152
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54200810
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
616000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
542000
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
747457000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
625048000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-835399000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-734611000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-87326000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-109021000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31316000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23746000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
84359000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69108000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19825000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16933000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
54792000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
227075000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
136969000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26114000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29856000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
63181000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
78389000
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
401000
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
278000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
815000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
464000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
48493000
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
51542000
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
40957000
us-gaap Costs And Expenses
CostsAndExpenses
139966000
us-gaap Costs And Expenses
CostsAndExpenses
118065000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-25428000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11101000
us-gaap Operating Income Loss
OperatingIncomeLoss
-76785000
us-gaap Operating Income Loss
OperatingIncomeLoss
-39676000
CY2020Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-13374000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-13374000
CY2020Q3 us-gaap Interest Expense
InterestExpense
6882000
CY2019Q3 us-gaap Interest Expense
InterestExpense
5715000
us-gaap Interest Expense
InterestExpense
18763000
us-gaap Interest Expense
InterestExpense
16846000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-633000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
353000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
280000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1261000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-46317000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16463000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-108642000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-55261000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7854000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7854000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-38463000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-16463000
us-gaap Net Income Loss
NetIncomeLoss
-100788000
us-gaap Net Income Loss
NetIncomeLoss
-55261000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38463000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16463000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-100788000
us-gaap Profit Loss
ProfitLoss
-55261000
us-gaap Share Based Compensation
ShareBasedCompensation
11122000
us-gaap Share Based Compensation
ShareBasedCompensation
10468000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
8169000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
6790000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1218000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1262000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-55261000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.33
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.81
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.12
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58233988
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49373156
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55682379
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49157055
us-gaap Profit Loss
ProfitLoss
-100788000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-13374000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-7854000
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-838000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
2194000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
7113000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
395000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1085000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3533000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-959000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-8702000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
6921000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-81679000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37059000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
283000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
318000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
133190000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
594000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
58446000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
36750000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-75027000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
35838000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
218245000
omer Payment For Purchase Of Capped Call
PaymentForPurchaseOfCappedCall
23223000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
125638000
omer Proceeds From Termination Of Capped Call Contracts
ProceedsFromTerminationOfCappedCallContracts
7549000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
93675000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4978000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5034000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
889000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
813000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
174697000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4221000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
17991000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3000000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3084000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5861000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21075000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8861000
us-gaap Interest Paid Net
InterestPaidNet
8564000
us-gaap Interest Paid Net
InterestPaidNet
6811000
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
216000
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
886000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 12.25pt;">Organization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We are a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system, addiction and immune-related diseases, including cancers. Our first drug product, OMIDRIA, is marketed in the United States (U.S.) for use during cataract surgery or intraocular lens replacement.</p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
153500000
us-gaap Operating Income Loss
OperatingIncomeLoss
-76800000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-81700000
omer Percentage Of Annual Cataract Surgery Procedures To Cms Medicare Part B Beneficiaries
PercentageOfAnnualCataractSurgeryProceduresToCmsMedicarePartBBeneficiaries
0.45
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 12.25pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include revenue recognition, stock-based compensation expense and accruals for clinical trials, manufacturing of drug product and clinical drug supply and other contingencies. We base our estimates on historical experience and on various other factors, including the impact of the COVID-19 pandemic, that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.</p>
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1466282
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3044999
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1789105
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2846730
CY2020Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
37218000
CY2019Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
35074000
CY2020Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
161000
CY2019Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
111000
CY2020Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
37379000
CY2019Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
35185000
CY2020Q3 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
8700000
CY2019Q4 omer Trade Receivable Chargeback Allowances
TradeReceivableChargebackAllowances
1600000
CY2020Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
79000
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
91000
CY2020Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
797000
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
338000
CY2020Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
666000
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
718000
CY2020Q3 us-gaap Inventory Net
InventoryNet
1542000
CY2019Q4 us-gaap Inventory Net
InventoryNet
1147000
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10203000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9864000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7253000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6035000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2950000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3829000
CY2019Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1200000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1300000
CY2020Q3 omer Accrued Sales Rebates Fees And Discounts Current
AccruedSalesRebatesFeesAndDiscountsCurrent
10201000
CY2019Q4 omer Accrued Sales Rebates Fees And Discounts Current
AccruedSalesRebatesFeesAndDiscountsCurrent
10870000
CY2020Q3 omer Accrued Contract Research Costs
AccruedContractResearchCosts
8813000
CY2019Q4 omer Accrued Contract Research Costs
AccruedContractResearchCosts
24107000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6415000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3546000
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5479000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3610000
CY2020Q3 us-gaap Interest Payable Current
InterestPayableCurrent
3736000
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1640000
CY2020Q3 omer Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
1482000
CY2019Q4 omer Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
1982000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
822000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
872000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
36948000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
46627000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21100000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3100000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0
CY2019 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0
CY2020Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
320030000
CY2020Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
80867000
CY2020Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
6355000
CY2020Q3 us-gaap Long Term Debt
LongTermDebt
232808000
CY2019Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
210000000
CY2019Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
47660000
CY2019Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
4127000
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
158213000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2282000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26116000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
27082000
CY2020Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
2150000
CY2019Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
2973000
CY2020Q3 omer Lease Right Of Use Asset
LeaseRightOfUseAsset
28266000
CY2019Q4 omer Lease Right Of Use Asset
LeaseRightOfUseAsset
30055000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2619000
CY2020Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1135000
CY2019Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1222000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28767000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30772000
CY2020Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
950000
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1546000
CY2020Q3 omer Lease Liability
LeaseLiability
33471000
CY2019Q4 omer Lease Liability
LeaseLiability
35822000
us-gaap Operating Lease Cost
OperatingLeaseCost
4540000
us-gaap Operating Lease Cost
OperatingLeaseCost
3121000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1039000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
984000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
224000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
248000
us-gaap Variable Lease Cost
VariableLeaseCost
1715000
us-gaap Variable Lease Cost
VariableLeaseCost
1699000
us-gaap Sublease Income
SubleaseIncome
929000
us-gaap Sublease Income
SubleaseIncome
673000
us-gaap Lease Cost
LeaseCost
6589000
us-gaap Lease Cost
LeaseCost
5379000
us-gaap Operating Lease Payments
OperatingLeasePayments
6490000
us-gaap Operating Lease Payments
OperatingLeasePayments
4962000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
224000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
248000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
889000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
813000
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
omer Number Of Options To Extend Lease
NumberOfOptionsToExtendLease
2
CY2020Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
48200000
CY2020Q3 omer Long Term Purchase Commitment Termination Fee
LongTermPurchaseCommitmentTerminationFee
35900000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000000.0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
550342
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000000.0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
513790
CY2020Q3 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
6900000
CY2020Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
14.50
CY2020Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
93700000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-109021000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2712000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3476000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-29031000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-131864000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
66000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3822000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-33294000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-161270000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
93675000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2200000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3824000
CY2020Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
61628000
CY2020Q3 omer Adjustments To Additional Paid In Capital For Purchase Of Capped Calls
AdjustmentsToAdditionalPaidInCapitalForPurchaseOfCappedCalls
23223000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
-22073000
CY2020Q3 omer Adjustments To Additional Paid In Capital For Termination Capped Call Contracts
AdjustmentsToAdditionalPaidInCapitalForTerminationCappedCallContracts
8387000
CY2020Q3 omer Adjustments To Additional Paid In Capital For Tax Benefit Related To Issuance Of Convertible Senior Debt Net Of Extinguishment
AdjustmentsToAdditionalPaidInCapitalForTaxBenefitRelatedToIssuanceOfConvertibleSeniorDebtNetOfExtinguishment
12011000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-38463000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-87326000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-100156000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
108000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3374000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-24345000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-121019000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1600000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3598000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-14453000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-130274000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3326000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3496000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-16463000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-139915000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3824000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3496000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11122000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10468000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11207931
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.72
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2074460
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.36
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
550342
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
9.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
635433
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
11.29
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12096616
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.98
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M12D
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3433000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
11689261
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.93
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y1M6D
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
3432000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
8407551
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.38
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y1M6D
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3426000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7900000

Files In Submission

Name View Source Status
0001558370-20-013359-index-headers.html Edgar Link pending
0001558370-20-013359-index.html Edgar Link pending
0001558370-20-013359.txt Edgar Link pending
0001558370-20-013359-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
omer-20200930.xsd Edgar Link pending
omer-20200930x10q.htm Edgar Link pending
omer-20200930x10q006.jpg Edgar Link pending
omer-20200930x10q_htm.xml Edgar Link completed
omer-20200930xex10d1.htm Edgar Link pending
omer-20200930xex31d1.htm Edgar Link pending
omer-20200930xex31d2.htm Edgar Link pending
omer-20200930xex32d1.htm Edgar Link pending
omer-20200930xex32d2.htm Edgar Link pending
omer-20200930_cal.xml Edgar Link unprocessable
omer-20200930_def.xml Edgar Link unprocessable
omer-20200930_lab.xml Edgar Link unprocessable
omer-20200930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending